Skip to Main Content


Current Issue
Volume 4,
Issue 6,
March 24, 2020

Featured Content

Blood Advances Editor-in-Chief Search is Open

The American Society of Hematology is looking for its next Editor-in-Chief of Blood Advances. All members of ASH are encouraged to submit a letter of intent if they are interested in the position or provide the name of a potential candidate. 

Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL

Adult T-cell leukemia/lymphoma (ATL) is a malignancy associated with infection by the human T-cell leukemia virus type-1 (HTLV-1), which carries a poor prognosis. Only a minority of patients infected with HTLV-1 progress to ATL. However, there is a need for biomarkers to identify patients who progress earlier in their course where therapy may be more effective. Guerrero and colleagues identified such a biomarker that may aid in an earlier, more specific diagnosis.

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Ceriani and colleagues analyzed baseline positron-emission tomography/computed tomography biomarkers in patients with diffuse large B-cell lymphoma enrolled on the SAKK38/07 study of the Swiss Group for Clinical Cancer Research. Using prognostic models, they found that patients with both high metabolic tumor volume and elevated metabolic heterogeneity have poorer outcomes. This group of patients might benefit from treatment intensification.

Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasms are rare disorders with a dismal prognosis. Nomburg and colleagues performed a comprehensive metagenomic analysis of patients with this disease to explore its pathophysiology.

Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling

RUNX1 is frequently mutated in acute leukemia. Bellissimo and colleagues explored the role of RUNX1 in innate immune signaling in a study, demonstrating a role for this pathway in the production of inflammatory cytokines from neutrophils. 

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

In this study, Jain and colleagues report the first integrated analysis of the clinical and genomic characteristics of aggressive histology mantle cell lymphoma (AH-MCL). Their findings identify the unique risks of de novo AH-MCL vs transformed MCL based on both the genomic profile and expression of the proliferation marker Ki67.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal